Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the ...

Please provide your email address to receive an email when new articles are posted on . In patients with type 2 diabetes, CagriSema lowered HbA1c to a greater degree than semaglutide at 68 weeks.

Semaglutide led to significant reductions in body weight, blood pressure, cholesterol, and HbA1c, but improvements were smaller than in clinical trials. Patients without diabetes experienced greater ...

Semaglutide or tirzepatide should be first-line drugs for obesity and most of its related complications, new guidance from the European Association for the Study of Obesity recommended. The authors of ...